Navigation Links
Therapure Biopharma Inc. signs multi-year manufacturing agreement with LFB Biomedicaments
Date:2/1/2010

Therapure will build a dedicated production facility to support global markets for rare plasma proteins

Toronto, ON (PRWEB) February 1, 2010 -- Therapure Biopharma Inc. and LFB Biomedicaments, a wholly owned subsidiary of LFB S.A. a French biopharmaceutical company, today announced the signing of a toll manufacturing agreement under which Therapure will manufacture key plasma proteins to support an expansion by LFB into global plasma derived medicinal markets. Financial terms were not disclosed.

Under the terms of the agreement, Therapure will be responsible for the manufacture of two major plasma proteins and LFB will remain responsible for global regulatory approvals and marketing of these products. Therapure will retrofit its Health Canada licensed manufacturing facility to accommodate the installation of LFB proprietary technology and processes necessary to meets its manufacturing obligations.

The companies expect the facility to be completed in 2011. Qualification and validation process, including regulatory batches will be performed in 2012 in order to complete the regulatory approval process in the course of 2013.

The global market for plasma proteins is expected to grow at a rate of 6% over the next several years. These proteins extracted directly from human plasma include clotting factors that are crucial to patients with congenital or acquired bleeding disorders should be made widely available to these communities. Even though there are sometimes recombinant alternatives to a selection of these proteins, significant investments of time and money are required to bring new sources of supply to market. Therapure will produce these plasma-derived products using LFB’s existing technologies shortening in this manner the time required to bring the increased supply onto the market.

“We are proud to have been chosen by LFB as its contract manufacturer to support this important market expansion” said Thomas Wellner, President and CEO of Therapure. “We will be making a substantial investment in manufacturing capacity to meet LFB’s needs and to provide them with a more globally diversified and secure supply chain for these life-saving products,” continued Mr. Wellner.

"LFB is engaged on rare diseases management and is developing its manufacturing capacities to provide patients with the specific medicines they need" explained Pierre-Francois Falcou, Head of International Operations for LFB. “Their commitment of time and capital to retrofit their Toronto, Canada facility has made us confident that Therapure will be well positioned to significantly contribute to the global expansion of LFB which include North America for added value proteins” concluded Christian Béchon, President and CEO of LFB.

About Therapure Biopharma Inc.:
Therapure Biopharma Inc. is an integrated biopharmaceutical company that develops, manufactures, purifies and packages therapeutic proteins. As a contract development and manufacturing organization (CDMO) Therapure Biopharma applies scientific, manufacturing, and downstream purification expertise with an intimate understanding of advanced biology, complex proteins, and regulatory processes to develop effective and innovative solutions to advance products from discovery to market for its clients. Therapure’s Health Canada licensed 130,000 sq.ft. facility, includes manufacturing, research and quality control laboratories and a cGMP warehouse, and is built to U.S. FDA, EMEA, MHRA and Health Canada standards for the aseptic handling and purification of proteins.
For more information, please visit: www.therapurebio.com

About LFB:
LFB is a biopharmaceutical group that develops, manufactures and markets medicinal products for the treatment of serious and often rare diseases in several major therapeutic fields, namely Hemostasis, Immunology and Intensive Care.

LFB Group is the leading manufacturer of plasma-derived medicinal products in France and 6th worldwide and is also among the leading European companies for the development of monoclonal antibodies and new-generation proteins based on biotechnologies.

With its strong focus on research, the LFB Group is pursuing a growth strategy that seeks to extend its activities at international level and develop innovative therapies.

LFB’s 2008 turnover reaches 353 million, of which 67 million were dedicated to the R&D effort.LFB markets its products in 20 countries and is present in Germany and the UK since 2007 and in Brazil since 2004. Christian Béchon is president and CEO of the LFB Group (1531 employees).
For more information, please visit www.lfb.fr

Company Contacts:

Thomas Wellner, President and CEO
Therapure Biopharma Inc.
+1 905 286-6204
ceo (at) therapurebio (dot) com

Sandrine Charrières, Corporate Communications Director
LFB S.A.
+33 169 82 72 80
charrieres (at) lfb (dot) fr

###

Read the full story at http://www.prweb.com/releases/2010/02/prweb3541474.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Therapure Biopharma Inc. Commissions its Commercial-Scale Lyophilizer
2. Microbix and Therapure Biopharma Form Partnership to Expand Water-Based Supplies to the Pharma Industry
3. Therapure Biopharma Inc. and YM BioSciences Inc. Announce Partnership
4. Therapure Biopharma Inc. and Akorn, Inc. Announce Strategic Supply Contract
5. Therapure Biopharma Inc. Announces Delivery of its First Commercial-Scale Lyophilizer
6. Therapure Biopharma Inc. and LFB Biotechnologies Announce Development Services Contract for New Therapeutic Protein
7. PDL BioPharma Announces Two $0.50 Dividends in 2010
8. Seven More Biopharmaceutical Research Companies Join PhRMA
9. BioProcess International Launches a New and Improved Website for Biopharmaceutical Managers and Scientists
10. Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009
11. Leading Biopharmaceutical Company Selects Stimar for Code of Conduct Regulation Training
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Therapure Biopharma Inc. signs multi-year manufacturing agreement with LFB Biomedicaments 
(Date:12/7/2016)... ... December 07, 2016 , ... "Today, MHA ... most comprehensive mental health systems reform legislation in more than fifty years. We ... the commitment of our elected officials to improving mental health services and supports ...
(Date:12/7/2016)... ... December 07, 2016 , ... Silhouette Instalift is a simple, ... and tightening the skin of the face to create more youthful features. While ... very little downtime, Silhouette Instalift is a novel, minimally invasive facial procedure that ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... a purchase price of approximately $17.4 million (net of the cash acquired), ... approximately $13.2 million. Headquartered in Barcelona, Spain, Presence is a leading provider ...
(Date:12/7/2016)... Valley, CA (PRWEB) , ... December 07, 2016 , ... ... be used in several ways to restore a more youthful appearance to the face. ... now offer Sculptra, along with a variety of other treatments, to rejuvenate and renew ...
(Date:12/7/2016)... , ... December 07, 2016 , ... They are musicians ... sisters and wives, brothers and fathers, from New England and around the nation. What ... stigma, and are brought together in a beautiful and compelling new photographic exhibit debuting ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016 Henry Schein, Inc. ... health care products and services to office-based dental, animal health ... percent equity investment in Marrodent, one of Poland,s ... approximately $32 million. This transaction was announced on August 30, ... in Poland since 2014, and Marrodent ...
(Date:12/8/2016)... Research and Markets has announced the addition of ... their offering. ... The report provides separate comprehensive analytics for the ... Rest of World. Annual estimates and forecasts are provided ... provided for these markets. Market data and analytics are derived from primary ...
(Date:12/7/2016)... , Dec. 7, 2016 "Lantus (Insulin Glargine) Biosimilar Clinical ... on 37 biosimilar version of Lantus drug in clinical pipeline. Currently 5 ... , Japan , Kenya , ... Germany , China , Slovakia ... 1 & 2 diabetes mellitus. The patent on Lantus expired in 2014. ...
Breaking Medicine Technology: